CERS
Price
$1.49
Change
+$0.02 (+1.36%)
Updated
Mar 11 closing price
Capitalization
342.62M
50 days until earnings call
VMD
Price
$7.80
Change
+$0.40 (+5.41%)
Updated
Mar 11 closing price
Capitalization
363.54M
61 days until earnings call
Ad is loading...

CERS vs VMD

Header iconCERS vs VMD Comparison
Open Charts CERS vs VMDBanner chart's image
Cerus
Price$1.49
Change+$0.02 (+1.36%)
Volume$1.19M
Capitalization342.62M
Viemed Healthcare
Price$7.80
Change+$0.40 (+5.41%)
Volume$224.65K
Capitalization363.54M
CERS vs VMD Comparison Chart
Loading...
CERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CERS vs. VMD commentary
Mar 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CERS is a Hold and VMD is a Hold.

Ad is loading...
COMPARISON
Comparison
Mar 12, 2025
Stock price -- (CERS: $1.49 vs. VMD: $7.81)
Brand notoriety: CERS and VMD are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: CERS: 79% vs. VMD: 206%
Market capitalization -- CERS: $342.62M vs. VMD: $363.54M
CERS [@Medical Specialties] is valued at $342.62M. VMD’s [@Medical Specialties] market capitalization is $363.54M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CERS’s FA Score shows that 0 FA rating(s) are green whileVMD’s FA Score has 0 green FA rating(s).

  • CERS’s FA Score: 0 green, 5 red.
  • VMD’s FA Score: 0 green, 5 red.
According to our system of comparison, CERS is a better buy in the long-term than VMD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CERS’s TA Score shows that 2 TA indicator(s) are bullish while VMD’s TA Score has 4 bullish TA indicator(s).

  • CERS’s TA Score: 2 bullish, 5 bearish.
  • VMD’s TA Score: 4 bullish, 2 bearish.
According to our system of comparison, VMD is a better buy in the short-term than CERS.

Price Growth

CERS (@Medical Specialties) experienced а -5.70% price change this week, while VMD (@Medical Specialties) price change was +2.63% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -1.41%. For the same industry, the average monthly price growth was -7.41%, and the average quarterly price growth was -3.15%.

Reported Earning Dates

CERS is expected to report earnings on May 01, 2025.

VMD is expected to report earnings on May 12, 2025.

Industries' Descriptions

@Medical Specialties (-1.41% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VMD($364M) has a higher market cap than CERS($343M). VMD YTD gains are higher at: -2.618 vs. CERS (-3.247). VMD has higher annual earnings (EBITDA): 36.7M vs. CERS (-26.34M). CERS has more cash in the bank: 65.9M vs. VMD (12.8M). VMD has less debt than CERS: VMD (10.3M) vs CERS (96M). VMD has higher revenues than CERS: VMD (183M) vs CERS (156M).
CERSVMDCERS / VMD
Capitalization343M364M94%
EBITDA-26.34M36.7M-72%
Gain YTD-3.247-2.618124%
P/E RatioN/A37.52-
Revenue156M183M85%
Total Cash65.9M12.8M515%
Total Debt96M10.3M932%
FUNDAMENTALS RATINGS
CERS vs VMD: Fundamental Ratings
CERS
VMD
OUTLOOK RATING
1..100
6365
VALUATION
overvalued / fair valued / undervalued
1..100
46
Fair valued
66
Overvalued
PROFIT vs RISK RATING
1..100
10070
SMR RATING
1..100
9370
PRICE GROWTH RATING
1..100
8462
P/E GROWTH RATING
1..100
10078
SEASONALITY SCORE
1..100
n/a75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CERS's Valuation (46) in the Medical Specialties industry is in the same range as VMD (66) in the null industry. This means that CERS’s stock grew similarly to VMD’s over the last 12 months.

VMD's Profit vs Risk Rating (70) in the null industry is in the same range as CERS (100) in the Medical Specialties industry. This means that VMD’s stock grew similarly to CERS’s over the last 12 months.

VMD's SMR Rating (70) in the null industry is in the same range as CERS (93) in the Medical Specialties industry. This means that VMD’s stock grew similarly to CERS’s over the last 12 months.

VMD's Price Growth Rating (62) in the null industry is in the same range as CERS (84) in the Medical Specialties industry. This means that VMD’s stock grew similarly to CERS’s over the last 12 months.

VMD's P/E Growth Rating (78) in the null industry is in the same range as CERS (100) in the Medical Specialties industry. This means that VMD’s stock grew similarly to CERS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CERSVMD
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
65%
Momentum
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
70%
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 8 days ago
78%
Bullish Trend 15 days ago
78%
Declines
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 7 days ago
77%
BollingerBands
ODDS (%)
N/A
Bullish Trend 1 day ago
74%
Aroon
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
81%
View a ticker or compare two or three
Ad is loading...
CERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FTPIX70.77N/A
N/A
Invesco Technology R5
KSOCX166.21N/A
N/A
Kinetics Small Cap Opportunities Adv C
VPRAX28.19N/A
N/A
VY® T. Rowe Price Capital Apprec R6
FNDMX11.93N/A
N/A
Fidelity Series Sust Non-US Dev Mrkt Fd
MSILX18.63-0.12
-0.64%
iMGP Intl Instl

CERS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CERS has been loosely correlated with LAB. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if CERS jumps, then LAB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CERS
1D Price
Change %
CERS100%
+1.36%
LAB - CERS
44%
Loosely correlated
+5.56%
MASS - CERS
41%
Loosely correlated
+14.90%
OFIX - CERS
40%
Loosely correlated
+2.15%
ICUI - CERS
39%
Loosely correlated
+6.87%
NNOX - CERS
39%
Loosely correlated
+0.18%
More